Marimed (MRMD) CCO Ryan Crandall Receives RSU Shares

What Happened Ryan Crandall, Chief Commercial Officer of Marimed, reported the conversion/vesting of 6,046 restricted stock units (RSUs) into 6,046 shares of common stock on 2026-09-28. The issuer withheld 2,095 of those shares to satisfy tax withholding obligations (priced at $0.08/share, total ~$161), leaving a net increase of 3,951 shares to Crandall’s beneficial ownership. The RSU conversion is reported as a derivative conversion (transaction code M) with the withholding shown as a disposition for tax purposes (code F).

Key Details

• Transaction date: 2026-09-28
• Conversion: 6,046 RSUs → 6,046 common shares (exercise/conversion of derivative, code M) at $0.00 exercise price
• Tax withholding: 2,095 shares withheld (code F) at $0.08/share = $161
• Net shares received: 6,046 − 2,095 = 3,951 shares
• Shares owned after transaction: not specified in the filing
• Footnotes: F1 — RSUs convert one-for-one to common stock; F2 — shares withheld to satisfy tax withholding; F3 — RSUs were granted 3/28/2024 and remaining RSUs under the grant vest in full on 3/28/2027
• Filing timeliness: reported on 2026-09-28 (same date as transaction period) — not indicated as late

Context This was a routine equity award vesting (RSU conversion) rather than an open-market purchase or sale. The withholding of shares to cover taxes is a common, administrative cashless process and does not represent a market sale by the insider. There is no indication in this filing of an open-market sale or a 10% owner transaction.